thalidomide has been researched along with Bradycardia in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Bradycardia: Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 6.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
| " However, long-term use of thalidomide has raised concern because of the high incidence of adverse events." | 6.61 | Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. ( Chen, M; He, Y; Lin, X; Liu, M; Mao, R; Wang, L, 2019) |
| "Both thalidomide and atenolol have been reported to cause bradycardia." | 5.35 | Syncope and sinus bradycardia from combined use of thalidomide and beta-blocker. ( Yamaguchi, T, 2008) |
| " We report the final results of a phase II trial of thalidomide as initial therapy for early-stage multiple myeloma in an attempt to delay progression to symptomatic disease." | 5.10 | Thalidomide as initial therapy for early-stage myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Iturria, N; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "Thalidomide was therefore suggested as atherapeutic intervention for the treatment of ALS." | 2.73 | Thalidomide causes sinus bradycardia in ALS. ( Borisow, N; Dullinger, JS; Linke, P; Maier, A; Meyer, T; Münch, C; Ohlraun, S; Splettstösser, G, 2008) |
| " However, long-term use of thalidomide has raised concern because of the high incidence of adverse events." | 2.61 | Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. ( Chen, M; He, Y; Lin, X; Liu, M; Mao, R; Wang, L, 2019) |
| "Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer." | 2.41 | Thalidomide in cancer. ( Mehta, J; Singhal, S, 2002) |
| "A 65-year-old male with multiple myeloma received chemotherapy which included cyclophosphamide, thalidomide and dexamethasone." | 1.39 | Negative chronotropic effects and coronary ischaemic abnormalities following thalidomide therapy. ( Ali, A; Hothi, SS; Malik, N; Thompson, A, 2013) |
| "Both thalidomide and atenolol have been reported to cause bradycardia." | 1.35 | Syncope and sinus bradycardia from combined use of thalidomide and beta-blocker. ( Yamaguchi, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M | 1 |
| Lin, X | 1 |
| Wang, L | 1 |
| He, Y | 1 |
| Chen, M | 1 |
| Mao, R | 1 |
| Ali, A | 1 |
| Hothi, SS | 1 |
| Thompson, A | 1 |
| Malik, N | 1 |
| Yamaguchi, T | 1 |
| Rajkumar, SV | 1 |
| Gertz, MA | 1 |
| Lacy, MQ | 1 |
| Dispenzieri, A | 1 |
| Fonseca, R | 1 |
| Geyer, SM | 1 |
| Iturria, N | 1 |
| Kumar, S | 1 |
| Lust, JA | 1 |
| Kyle, RA | 1 |
| Greipp, PR | 1 |
| Witzig, TE | 1 |
| Coutsouvelis, J | 1 |
| Corallo, CE | 1 |
| Fahdi, IE | 1 |
| Gaddam, V | 1 |
| Saucedo, JF | 1 |
| Kishan, CV | 1 |
| Vyas, K | 1 |
| Deneke, MG | 1 |
| Razek, H | 1 |
| Thorn, B | 1 |
| Bissett, JK | 1 |
| Anaissie, EJ | 1 |
| Anaisse, E | 1 |
| Barlogie, B | 1 |
| Mehta, JL | 1 |
| Meyer, T | 1 |
| Maier, A | 1 |
| Borisow, N | 1 |
| Dullinger, JS | 1 |
| Splettstösser, G | 1 |
| Ohlraun, S | 1 |
| Münch, C | 1 |
| Linke, P | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)[NCT00231140] | Phase 2 | 40 participants | Interventional | 2005-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Bradycardia
| Article | Year |
|---|---|
Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review.
Topics: Adult; Bradycardia; Coronary Sinus; Crohn Disease; Heart Rate; Humans; Intestinal Mucosa; Male; Thal | 2019 |
Thalidomide in cancer.
Topics: Angiogenesis Inhibitors; Bradycardia; Exanthema; Humans; Interleukin-2; Interleukin-6; Neoplasms; Pe | 2002 |
3 trials available for thalidomide and Bradycardia
| Article | Year |
|---|---|
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Bradycardia during therapy for multiple myeloma with thalidomide.
Topics: Bradycardia; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide | 2004 |
Thalidomide causes sinus bradycardia in ALS.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents; Arrhythmia, Sinus; Bradycardia | 2008 |
3 other studies available for thalidomide and Bradycardia
| Article | Year |
|---|---|
Negative chronotropic effects and coronary ischaemic abnormalities following thalidomide therapy.
Topics: Aged; Bradycardia; Coronary Vasospasm; Electrocardiography; Humans; Immunosuppressive Agents; Male; | 2013 |
Syncope and sinus bradycardia from combined use of thalidomide and beta-blocker.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Drug Therapy, Combination; Heart Rate; Humans; Male; | 2008 |
Thalidomide-induced bradycardia and its management.
Topics: Aged; Bradycardia; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiograp | 2004 |